Nefazodone in the treatment of generalized social phobia: A randomized, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 68, Issue 2, 2007, Pages 288-295

  Van Ameringen, Michael ^a,g   Mancini, Catherine ^a   Oakman, Jonathan ^b   Walker, John ^c   Kjernisted, Kevin ^d   Chokka, Pratap ^e   Johnston, David ^f   Bennett, Mark ^g   Patterson, Beth ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c Department of Clinical Health Psychology ^*  (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e GREY NUNS COMMUNITY HOSPITAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; NEFAZODONE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; INDIGESTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

EID: 33847609653     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0215     Document Type: Article

References (73)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
3. Shields M. Social anxiety disorder: beyond shyness. Health Rep 2004;15(suppl):45-61
4. Offord DR, Boyle MH, Campbell D, et al. One year prevalence of psychiatric disorder in Ontarians 15-64 years of age. Can J Psychiatry 1996;41:559-563
5. Stein MB, Torgrud LJ, Walker JR. Social phobia symptoms, subtypes, and severity: findings from a community survey. Arch Gen Psychiatry 2000;57:1046-1052
6. Van Ameringen M, Mancini C, Farvolden P. The impact of anxiety disorders on educational achievement. J Anxiety Disord 2003;17:561-571
7. Liebowitz MR, Gorman JM, Fyer AJ, et al. Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry 1985;42:729-736
8. Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry 1996;27:1-9
9. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991;48:938-945
10. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300
11. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-1141
12. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand 1995;92:351-358
13. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine: a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29
14. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17:255-260
15. Versiani M, Nardi AE, Mundim FD, et al. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11(suppl 3):83-88
16. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-428
17. Versiani M, Egidio N, Figueira I, et al. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasilerio de Psiquiatria 1997;46:167-171
18. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-134
19. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760
20. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-1013
21. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371
22. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281
23. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30
24. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:785-792
25. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713
26. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999;175:120-126
27. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999;100:193-198
28. Lepola U, Bergtholdt B, St. Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004;65:222-229
29. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:488-496
30. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-396
31. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348
32. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-149
33. Van Ameringen M, Mancini C, Pipe B, et al. Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 2004;9:753-762
34. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002;63(suppl 1):10-17
35. Trivedi MH, Rush AJ, Pan J-Y, et al. Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001;62:158-163
36. Ninan PT, Rush AJ, Crits-Christoph P, et al. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 2002;63:434-441
37. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
38. Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996;57(suppl 2):19-23
39. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-805
40. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2):15-18
41. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
42. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-38
43. Letter. Available at: www.fda.gov/ohrms/dockets/dailys/03/Nov03/110303/ 03p-0090-sup0001-vol1.pdf. Accessibility verified January 3, 2007
44. Letter. Available at: www.fda.gov/ohrms/dockets/dailys/04/June04/062404/ 03p-0090-pdn00001-vol1.pdf. Accessibility verified January 3, 2007
45. Letter. Available at: www.fda.gov/medwatch/SAFETY/2002/serzone_deardoc. pdf. Accessibility verified January 3, 2007
46. Table 2. Health Canada, Canadian Adverse Reaction Newsletter 2003;13. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n1_e. html. Accessibility verified January 3, 2007
47. World Health Organization. Nefazodone. WHO Pharmaceuticals Newsletter 2003;1:7-8
48. Worthington JJ, Zucker BG, Fones CS, et al. Nefazodone for social phobia: a clinical case series. Depress Anxiety 1998;8:131-133
49. Van Ameringen M, Mancini C, Oakman JM. Nefazodone in social phobia. J Clin Psychiatry 1999;60:96-100
50. 2 antagonist nefazodone. Presented at the Anxiety Disorders Association of America's 20th National Conference; March 23-26, 2003; Washington, DC
51. Keller MB, Klein DN, Hirschfeld RM, et al. Results of the DSM-IV mood disorders field trial. Am J Psychiatry 1995;152:843-849
52. Guy W. ECDEU Assessment Manual for Psychopharmacoloy. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
53. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
54. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173
55. Connor KM, Davidson JR, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000;176:379-386
56. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998:36:455-470
57. Beck AT, Ward CH, Mendleson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
58. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897
59. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983
60. Hays RD, Sherboume CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-227
61. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 2003;18:29-40
62. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22:257-262
63. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71:1058-1067
64. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998;59(suppl 2):85-93
65. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21
66. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-315
67. Owens MJ, Ieni JR, Knight DL, et al. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci 1995;57:PL373-PL380
68. Narayan M, Anderson G, Cellar J, et al. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol 1998;18:67-71
69. Preskorn SH. Imipramine, mirtazapine, and nefazodone: multiple targets. J Pract Psychiatr Behav Health 2000;97-102
70. Wander TJ, Nelson A, Okazaki H, et al. Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol 1986;132:115-121
71. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76:511-527
72. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209
73. Meyer UA, Zanger UM, Skoda RC, et al. Genetic polymorphisms of drug metabolism. Prog Liver Dis 1990;9:307-323